Cargando…

Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study

Aim: To assess the efficacy of focal photocoagulation of capillary macroaneurysms (CMA) to reduce the burden of intravitreal injections (IVI) in patients with macular edema (ME). Materials and Methods: Retrospective multicenter study in patients with diabetic ME or ME secondary to retinal vein occlu...

Descripción completa

Detalles Bibliográficos
Autores principales: Séjournet, Lucas, Kodjikian, Laurent, Elbany, Sandra, Allignet, Benoit, Agard, Emilie, Chaperon, Mayeul, Billant, Jérémy, Denis, Philippe, Mathis, Thibaud, Burillon, Carole, Dot, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966640/
https://www.ncbi.nlm.nih.gov/pubmed/36839631
http://dx.doi.org/10.3390/pharmaceutics15020308
_version_ 1784897067186913280
author Séjournet, Lucas
Kodjikian, Laurent
Elbany, Sandra
Allignet, Benoit
Agard, Emilie
Chaperon, Mayeul
Billant, Jérémy
Denis, Philippe
Mathis, Thibaud
Burillon, Carole
Dot, Corinne
author_facet Séjournet, Lucas
Kodjikian, Laurent
Elbany, Sandra
Allignet, Benoit
Agard, Emilie
Chaperon, Mayeul
Billant, Jérémy
Denis, Philippe
Mathis, Thibaud
Burillon, Carole
Dot, Corinne
author_sort Séjournet, Lucas
collection PubMed
description Aim: To assess the efficacy of focal photocoagulation of capillary macroaneurysms (CMA) to reduce the burden of intravitreal injections (IVI) in patients with macular edema (ME). Materials and Methods: Retrospective multicenter study in patients with diabetic ME or ME secondary to retinal vein occlusion (ME-RVO). CMA associated with ME were selectively photocoagulated. Patients were followed for one year after photocoagulation. Results: 93 eyes of 76 patients were included in this study. At 6 months after the laser (n = 93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 2.52 to 1.52 at 6 months, p < 0.001). The mean BCVA remained stable (0.32 and 0.31 logMAR at baseline and 6 months, p = 0.95). At 12 months (n = 81/93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 4.44 to 2.95 at 12 months, p < 0.001), while the mean BCVA remained stable (0.32 and 0.30 logMAR at baseline and 12 months, p = 0.16). Conclusion: Focal laser photocoagulation of CMA seems to be effective and safe for reducing the burden of IVI in patients with ME. Their screening during the follow-up should be considered closely.
format Online
Article
Text
id pubmed-9966640
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99666402023-02-26 Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study Séjournet, Lucas Kodjikian, Laurent Elbany, Sandra Allignet, Benoit Agard, Emilie Chaperon, Mayeul Billant, Jérémy Denis, Philippe Mathis, Thibaud Burillon, Carole Dot, Corinne Pharmaceutics Article Aim: To assess the efficacy of focal photocoagulation of capillary macroaneurysms (CMA) to reduce the burden of intravitreal injections (IVI) in patients with macular edema (ME). Materials and Methods: Retrospective multicenter study in patients with diabetic ME or ME secondary to retinal vein occlusion (ME-RVO). CMA associated with ME were selectively photocoagulated. Patients were followed for one year after photocoagulation. Results: 93 eyes of 76 patients were included in this study. At 6 months after the laser (n = 93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 2.52 to 1.52 at 6 months, p < 0.001). The mean BCVA remained stable (0.32 and 0.31 logMAR at baseline and 6 months, p = 0.95). At 12 months (n = 81/93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 4.44 to 2.95 at 12 months, p < 0.001), while the mean BCVA remained stable (0.32 and 0.30 logMAR at baseline and 12 months, p = 0.16). Conclusion: Focal laser photocoagulation of CMA seems to be effective and safe for reducing the burden of IVI in patients with ME. Their screening during the follow-up should be considered closely. MDPI 2023-01-17 /pmc/articles/PMC9966640/ /pubmed/36839631 http://dx.doi.org/10.3390/pharmaceutics15020308 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Séjournet, Lucas
Kodjikian, Laurent
Elbany, Sandra
Allignet, Benoit
Agard, Emilie
Chaperon, Mayeul
Billant, Jérémy
Denis, Philippe
Mathis, Thibaud
Burillon, Carole
Dot, Corinne
Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
title Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
title_full Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
title_fullStr Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
title_full_unstemmed Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
title_short Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
title_sort focal photocoagulation as an adjunctive therapy to reduce the burden of intravitreal injections in macula edema patients, the lyomac2 study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966640/
https://www.ncbi.nlm.nih.gov/pubmed/36839631
http://dx.doi.org/10.3390/pharmaceutics15020308
work_keys_str_mv AT sejournetlucas focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT kodjikianlaurent focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT elbanysandra focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT allignetbenoit focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT agardemilie focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT chaperonmayeul focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT billantjeremy focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT denisphilippe focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT mathisthibaud focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT burilloncarole focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study
AT dotcorinne focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study